XML 19 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Cash flows from operating activities:    
Net loss $ (7,544) $ (5,339)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 442 291
Amortization of deferred financing costs and debt discount 219 232
Joint Venture acquisition obligation accretion 0 17
Provision for expired inventory 340 0
Stock-based compensation expense 199 317
Loss on asset disposal 2 2
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Accounts receivable 335 155
Inventories 7 (206)
Other current assets (65) (408)
Other assets 24 (211)
Accounts payable and accrued expenses (484) 176
Deferred revenues 12 (4)
Long-term deferred rent 0 (80)
Net cash used in operating activities (4,827) (5,058)
Cash flows from investing activities:    
Purchases of property and equipment /long-lived assets (5) (69)
Net cash used in investing activities (1,163) (69)
Cash flows from financing activities:    
Principal payments on long-term obligations (1,770) 0
Joint Venture purchase payments 0 (500)
Proceeds from sale of common stock, net 1,435 562
Net cash (used in) provided by financing activities (335) 62
Effect of exchange rate changes on cash and cash equivalents 20 85
Net decrease in cash and cash equivalents (6,305) (4,980)
Cash and cash equivalents at beginning of period 12,560 14,338
Cash and cash equivalents at end of period 6,255 9,358
Cash paid during period for:    
Interest 384 400
Azaya Therapeutics, Inc. [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
In process research and development acquired 1,686 0
Cash flows from investing activities:    
Purchases of property and equipment /long-lived assets (1,158) 0
Supplemental schedule of non-cash investing and financing activities:    
Common stock issued in payment for the assets acquired 2,311 0
Unpaid liabilities assumed in payment for the assets acquired from Azaya Therapeutics $ 279 $ 0